Background-Small coronary vessels supply small myocardial territories. The clinical significance of small-vessel stenoses is therefore questionable. Moreover, percutaneous coronary intervention (PCI) of nonfunctionally significant lesions does not improve clinical outcome and might be associated with potential procedural or stent related risks. The aim of this study was to assess the clinical outcome of fractional flow reserve (FFR)-guided PCI in the treatment of small coronary vessel lesions as compared with an angio-guided PCI.
P ercutaneous revascularization (PCI) of small coronary vessels represents 30 -50% of the catheter-based coronary intervention performed worldwide each year. [1] [2] [3] [4] [5] [6] The decision to proceed to PCI often relies solely on the basis of the angiographic evaluation of the stenosis severity. 7 Importantly, the Phantom trial showed no correlation between either angiographic or intravascular ultrasound (IVUS) and functional evaluation using fractional flow reserve (FFR) in the assessment of coronary stenosis in small vessels. Despite the morphological appearance, in fact, only one-third of the lesions seen in small vessels turned out to be functionally significant. 8 Small vessels generally supply limited myocardial mass, meaning that even in the presence of angiographi-cally significant stenosis, residual vascular lumen might still be sufficient to maintain perfusion to the subtended myocardial territory. 9, 10 Therefore, appropriate selection of which lesion should be considered for PCI is vital, especially because small vessels still represent a challenging lesion subset due to the high risk of restenosis and repeat revascularization. 11, 12 The use of drug-eluting stents (DES) in the treatment of small-vessel disease significantly improves long-term efficacy of percutaneous revascularization. [13] [14] [15] [16] [17] However, the success of DES in the treatment of small-vessel disease is potentially offset by increasing procedural costs, with a higher risk of late stent thrombosis on one hand and a higher bleeding risk on the other, secondary to prolonged dual antiplatelet therapy. 18 -20 A revascularization strategy guided by FFR has been demonstrated to be safe in lesions located in large vessels. [21] [22] [23] In addition, in multivessel disease, an FFR-guided PCI improved clinical outcome and has been proven to be cost-saving. 24, 25 Yet, no specific study with long-term clinical outcomes has been done to assess whether an FFR-guided PCI strategy is safer and associated with a better clinical outcome as compared with an angio-guided PCI strategy in the treatment of small-vessel disease. Therefore, the aim of the present retrospective registry is to evaluate the long-term clinical outcome of patients undergoing FFR-guided PCI of lesions in small vessels. Contemporary age-matched patients undergoing angio-guided PCI in small vessels were used as a reference group.
WHAT IS KNOWN
• There is no correlation between anatomic severity and functional severity of the stenosis in small-vessel disease. • In intermediate lesions and large-sized vessels, deferring PCI on the basis of a nonsignificant FFR is safe. • In patients with multivessel disease, an FFR-guided PCI strategy improves clinical outcome and reduces significantly the costs as compared with an angiographic-guided strategy.
WHAT THE STUDY ADDS
• In small-vessel disease, an FFR-guided PCI strategy compared with an angiographic-guided strategy is associated with a significant reduction in (1) major adverse cardiovascular events; (2) combined death or nonfatal myocardial infarction (MI); (3) nonfatal MI alone; and (4) target vessel revascularization. • This clinical benefit is achieved with a significant reduction in procedural costs.
Methods

Patient Population
In this retrospective registry, all patients treated with PCI from January 2004 to December 2008 for stable or unstable angina in a native small coronary vessel (defined as a reference vessel diameter Ͻ3 mm by quantitative coronary angiography [QCA] and size of the stent implanted Ͻ3 mm) were included. Exclusion criteria were (1) patients treated with PCI and stenting for a concomitant large vessel, that is, Ն3 mm; (2) bypass graft stenting; (3) patients presenting with ST-segment elevation MI or non-ST-segment elevation MI; and (4) PCI performed without stent implantation. According to the strategy adopted to guide the percutaneous revascularization, patients were grouped into an "angio-guided" PCI group, in which PCI was performed in an angiographically significant stenosis (by quantitative coronary angiography), and an "FFR-guided" PCI, in which PCI was performed in case of FFR Ͻ0.80 and deferred to optimal medical therapy in case of FFR Ն0.80.
Pressure Measurements
Myocardial FFR was measured using a 0.014-inch miniaturized pressure monitoring guide wire system (RADI PressureWire, St Jude Medical Systems) to record the distal coronary pressure. The wire was introduced through either a 6F or 7F guiding catheter, calibrated, advanced into the coronary artery, and, after equalization, positioned distal to the stenosis as previously described. 26, 27 Adenosine was administered to induce maximum hyperemia using either (1) intravenous adenosine at 140 g/kg per minute infusion or (2) intracoronary adenosine (using a 50-g bolus in most cases). In some cases (ie, FFR values close to 0.80), we used incremental doses of IC adenosine up to 150 g, provided the patient tolerated the lower dose, to ensure that maximum hyperemia was achieved. FFR was calculated as the ratio of mean hyperemic distal coronary pressure measured by the pressure wire to mean aortic pressure measured by the guiding catheter (Pd/Pa). An FFR threshold Ͻ0.80 was used to detect functionally significant lesions (eg, ischemic lesion). 9, 27 Coronary Angiography and Percutaneous Intervention The computer-based analysis system Siemens QuantCor.QCA (ACOM.PC 5.01, Siemens Medical Systems Inc, Malvern, PA), based on the CAAS II system (Pie Medical Imaging, Maastricht, The Netherlands) was used for offline QCA analysis. The contrast-filled catheter was used for calibration. Minimal lumen diameter (MLD), percent diameter stenosis (%DS) by QCA analysis, reference diameter, and lesion length were measured preferably on end-diastolic images. All QCA measurements were performed by 2 independent operators. In our laboratory, QCA intraobserver variability was determined by comparing MLD between 2 consecutive measurements by the same operator and expressed as mean difference. A mean difference of 0.08 mm was found between first and second MLD measurements (Pϭ0.84) performed by the same observer. The interobserver variability was determined by comparing MLD of the same coronary segment between 2 independent observers and expressed as mean difference. A mean difference of 0.11 mm was found between first and second observers (Pϭ0.34). Postprocedural therapies, including antiplatelet therapy, were prescribed according to current guidelines.
Data Collection and Follow-Up
This study complied with the Declaration of Helsinki and was approved by the local ethical committee. All patients provided written informed consent. All demographic, baseline clinical data, and procedure data were retrieved from the patient database at OLV Hospital, Aalst. Clinical follow-up was performed using hospital records and telephone interviews, and it was conducted up to 5 years. All events were classified and adjudicated by a physician not aware of the chosen strategy. The primary end point of the study was major adverse cardiac events (MACE) defined as cardiac death, nonfatal MI, and target vessel revascularization (TVR). TVR was defined as a repeated PCI or coronary artery bypass graft surgery involving the target vessel. Secondary end points were stent thrombosis (defined as an acute coronary syndrome with angiographic documentation of either target vessel occlusion or thrombus within or adjacent to the previously successfully stented segment) and periprocedural MI. MI was defined as previously described. 28, 29 Finally, bleeding complications (major Thrombolysis In Myocardial Infarction) and use of any transfusion during hospital stay were collected. 30 Angiographic follow-up was performed only in case of recurrent angina or coronary events. Costs of the equipment used during the index procedure were also evaluated.
Statistical Analysis
All analyses were performed with SPSS version 16 (SPSS Inc, Chicago, IL). Continuous variables are expressed as meanϮSD or median [interquartile range]. Categorical variables are reported as frequencies and percentages. Normal distribution was assessed by the Kolmogorov-Smirnov test. The Student t test or Mann-Whitney test was used to compare continuous variables, as appropriate. Comparisons between categorical variables were evaluated using the 2-tailed Fisher exact test or Pearson 2 test, as appropriate. To adjust for potential selection bias, a propensity score was built with a nonparsimonious method by means of logistic regression model relating stent group (angiography versus FFR) to pretreatment patient characteristics. 31 Specifically, all the variables listed in Table 1 and the baseline angiographic characteristics included in Table 2 were incorporated into the model and the score was then used into proportional hazards analyses as a covariate. Survival was evaluated by the unadjusted Kaplan-Meier method and Cox proportional hazard analysis. A probability value of Ͻ0.05 was considered statistically significant.
Results
Baseline Clinical, Angiographic, and Procedural Data
A total of 717 patients were included in this registry; 495 were treated with an angio-guided PCI strategy and 222 with an FFR-guided PCI strategy. In the FFR-guided group, 144 patients were deferred based on a negative FFR (FFR-DEFER), whereas the remaining 78 patients were treated with PCI, based on a positive FFR (FFR-PCI).
Baseline clinical characteristics are summarized in Table 1 . In the angio-guided group, patients were more frequently male and had more previous coronary artery bypass graft, with an ejection fraction significantly lower, yet within the normal range, as compared with patients of the FFR-guided group. In addition, an angio-guided PCI strategy was more frequently adopted in patients with unstable angina, whereas an FFR-guided strategy was more frequently adopted in patients with stable angina. Within the FFR-guided group, clinical characteristics of the patients did not differ among those with positive and negative FFR (data not shown).
Angiographic and procedural characteristics are presented in Table 2 . Stenosis in the left anterior descending artery was more frequent in the FFR-guided group, whereas stenosis in the left circumflex artery was more frequent in the angioguided group. In the angio-guided group, diameter stenosis was significantly higher, whereas minimal lumen diameter and reference diameter were significantly lower as compared with the FFR-guided group.
The number of vessels treated per patient was significantly higher in the angio-guided group as compared with the FFR-guided group. Multivessel PCI was performed only in a minority of patients, and more frequently in the FFR group. No difference in stent diameter and length was seen between the 2 groups. However the number of stents used per patient was significantly lower in the FFR group. The proportion of patients treated with a DES between the 2 groups was similar (43 versus 50%, Pϭ0.25). The type of DES used was also similar between the 2 groups (data not shown). Periprocedural MI occurred in 24 (5%) patients in the angio-guided group and in none of the patients in the FFR-guided group (Pϭ0.0008). No major bleedings were reported. Costs for the equipment used at the index procedure were significantly higher in the angio-guided group as compared with the FFR-guided group.
Clinical Outcomes
Clinical follow-up was obtained in 698 of 717 patients (97%). The median follow-up was 3.3 years (from 0.01-5 years). Kaplan-Meier survival curves showed no difference in terms of death, but a significantly lower rate of the combined death or nonfatal-MI, TVR, and MACE in patients treated with an FFR-guided PCI compared with an angio-guided PCI ( Figure  1 and Table 3 ). Propensity-adjusted Cox analysis showed a significantly lower rate of nonfatal MI, combined death or nonfatal MI, TVR, and MACE in patients with an FFRguided PCI as compared with an angio-guided PCI ( Table 3) . Stent thrombosis was rare and occurred in 6 patients in the angio-guided group and none in the FFR-guided PCI group.
Kaplan-Meier survival analysis for MACE in the angioguided PCI group, FFR-guided PCI group, and FFR-guided DEFER group is reported in Figure 2 . The MACE rate was significantly lower in the FFR-guided DEFER group compared with the angio-guided group (15% versus 29%, Pϭ0.002), but only a trend toward a lower MACE rate was seen between the FFR-guided PCI group and the angioguided group (23% versus 29%, Pϭ0. 19) group. In addition, there was a nonsignificant trend toward a lower MACE rate in the FFR-guided DEFER as compared with FFR-guided PCI group (15% versus 23%, Pϭ0.16 ).
Discussion
This is the largest retrospective registry of an FFR-guided PCI strategy in small-vessel disease with the longest clinical follow-up. Our findings demonstrate that FFR-guided PCI of small coronary vessel disease is safe and results in better clinical outcomes as compared with an angio-guided PCI. Our data also indicate that in addition to the observed clinical benefit, there is a significant reduction in procedural costs.
PCI in Small-Vessel Disease
Smaller vascular lumen diameter is a strong predictor of in-stent restenosis. [1] [2] [3] [4] [5] [6] 11, 12 The adoption of DES in smallvessel disease has significantly reduced in-stent restenosis and TVR as compared with bare metal stents. [13] [14] [15] [16] [17] The beneficial effect of DES, however, has invariably increased costs of PCI and has introduced unexpected device-related diseases, for example, the risk of late and very late stent thrombosis and the risk of bleeding potentially caused by the prolonged dual antiplatelet therapy. 18 -20 Nevertheless, smallvessel disease represents the lesion subset in which DES demonstrates the best cost-effectiveness at long-term follow-up. 16 In other words, when PCI of small-vessel disease is appropriately indicated, the potential intrinsic risks and the extra costs related to DES are acceptable as they are clearly offset by the additional clinical benefit. In contrast, when the indication is inappropriate, that is, in case of nonischemic lesions patients are exposed to an unacceptable risk.
The indication to perform PCI is often based on the angiographic severity of the coronary stenosis, which represents a poor predictor of the functional severity (ie, the potential of the stenosis to induce myocardial ischemia). 9, 27 Furthermore, the Phantom trial has shown that there is no correlation between the anatomic severity of a stenosis (as assessed by both angiography and IVUS) and the functional severity of the stenosis (as assessed by FFR) in small-vessel disease. In fact, only one-third of the lesions in small vessels were actually ischemic after FFR measurement. 8 Similarly, in our study, only 78 patients of 222 (35%) presenting with a small-vessel stenosis had an FFR Ͻ0.80. This finding is not surprising if we consider that small vessels generally supply a small myocardial mass and that the residual vascular lumen might be more than sufficient to preserve perfusion in the subtended myocardial territory. 10 Prospective studies are needed to specifically assess the functional anatomic mismatch potentially occurring in small vessels.
FFR-Guided PCI
FFR is a valuable tool to invasively assess the ischemic potential of a coronary stenosis. FFR has unequal spatial resolution, capable of unmasking a culprit stenosis even in the case of complex coronary artery disease, such as small-vessel and multivessel disease. 9,24 -27,32-42 Deferring PCI on the basis of a nonsignificant FFR has shown to be safe in intermediate lesions and large-sized vessels, such as proximal left anterior descending and left main coronary artery disease. [21] [22] [23] In addition, an FFR-guided PCI strategy not only improved clinical outcome as compared with an angio-guided strategy in patients with multivessel disease but also does so at a significantly reduced cost. 25, 43 Our study further extends these findings to patients with small-vessel disease. An FFR-guided PCI strategy was associated with a significant reduction in MACE as compared with an angio-guided strategy. With the exception of mortality and stent thrombosis, this superiority persisted also when the endpoints were individually analyzed. In fact, the FFRguided group had significantly lower combined death or nonfatal MI, nonfatal MI alone, and TVR. This clinical benefit was achieved with a significant reduction in procedural costs, mainly due to a reduced number of stents used in the FFR-guided group. In addition, of 222 patients undergoing FFR-guided PCI, 144 were deferred on the basis of a nonsignificant FFR measurement. These patients had a very favorable long-term clinical outcome (Figure 2) , with a trend toward lower MACE rate when compared with patients with a positive FFR undergoing PCI and with a significantly lower MACE rate when compared with patients undergoing an angio-guided PCI strategy. Despite many similarities, the present study differs substantially from the FAME study. This, in fact, is a retrospective single center registry aimed at assessing an FFR-guided PCI strategy in patients mostly with single-vessel disease (88%). In addition, stenting (performed with bare metal stents or DES) was attempted in small vessels (Ͻ2.75 mm), whereas in the FAME study, final vessel size (as estimated by size of the stent implanted) was Ͼ2.75 mm.
Our results are particularly remarkable when one considers that the clinical benefit derived from revascularizing small vessels is uncertain. Optimal medical therapy, in fact, might be more effective than PCI for treating small areas of ischemic myocardium, which is usually the case in a smallvessel stenosis. 10 Our observation of a 59% reduction in the risk of the combined end point of death or nonfatal MI and of a 54% reduction in the risk of MACE supports the concept that a functionally guided revascularization together with optimal medical therapy is beneficial even in small-vessel disease. Whether an FFR-guided PCI strategy plus optimal medical therapy of small-vessel disease is superior to a strategy of optimal medical therapy alone needs further investigation.
Study Limitations
This is a retrospective, nonrandomized study, and there were some differences in baseline clinical characteristics and presentation (ie, unstable angina was more frequent in the angio-guided group) between the 2 groups. To account for confounding factors that could potentially influence the clinical outcome, a propensity score analysis was performed. Even with the propensity score analysis, it must be acknowledged that factors cannot be accounted for that influence the operator's decision to adopt a particular strategy.
Only patients with stable and unstable angina were recruited. The inclusion of patients with non-ST-segment elevation MI or ST-segment elevation MI would have led to an even higher operator-dependent bias. Our results cannot be extended to this subset of patients.
We defined small-vessel disease by using both the vessel diameter and stent size Ͻ3.0 mm. By using these thresholds, we could identify a significant mismatch between anatomic and functional significance of the stenosis severity with only one-third of the lesions deemed angiographically significant with an FFR Ͻ0.80. Nevertheless, we cannot exclude that by using an even more stringent definition of small-vessel disease (ie, Յ2.5 mm), we could have probably identified many more nonsignificant stenosis, which were otherwise been considered for PCI on the angiographic evaluation. In addition, the angiographic evaluation was used to identify small-vessel disease. An IVUS assessment of the vessel size would have been more accurate. To minimize potential suboptimal assessment of vessel size, we paid particular attention to the following: (1) baseline angiogram was acquired after intracoronary nitrate administration with a 6F guiding catheter; (2) multiple orthogonal projections were acquired; (3) vessel size and stenosis severity were measured by QCA. In addition, patients with an implanted stent Ն3 mm (or with a final postdilatation with a balloon Ն3 mm) were excluded from our analysis.
Patients undergoing balloon angioplasty without stent implantation were excluded from our study. We cannot exclude that in some cases the operators might have decided to defer a procedure simply because the stenotic vessel was too small to be stented.
DES were evenly implanted in both groups, but only in half of the patients. We cannot exclude that clinical outcome could have been different if DES had been implanted in all patients, especially in terms of TVR. In addition, our investigation does not aim nor is powered to explore the potential impact on clinical outcome of a revascularization strategy, based on a selective DES implantation of small-vessel disease guided by FFR. Further investigations are warranted.
Last, the significant difference in the composite end point of death/MI is mostly driven by periprocedural MI. We are unable to discriminate between type 1 and 2 periprocedural MI; therefore, we cannot provide a causal link between myocardial damage occurring during the procedure and clinical outcome.
Conclusions
An FFR-guided PCI strategy in small artery stenoses is safe and results in better clinical outcomes as compared with an angio-guided PCI strategy. This additional clinical benefit is achieved with a significant reduction of procedural costs.
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